$0.19
(Market cap
$1,286 Mln
Revenue (TTM)
$408 Mln
P/E Ratio
--
P/B Ratio
1.4
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0 %
-
ROCE
-- %
-
Industry P/E
51.41
-
EV/EBITDA
17.6
-
Debt to Equity
0.3
-
Book Value
$--
-
EPS
$-0.4
-
Face value
--
-
Shares outstanding
152,538,780
6 Years Aggregate
CFO
$330.11 Mln
EBITDA
$328.23 Mln
Net Profit
$-145.47 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Certara (CERT)
| -4.5 | 12.0 | 61.4 | -22.6 | -19.5 | -23.2 | -- |
|
BSE Sensex
| -9.1 | 1.1 | 1.2 | -4.8 | 5.8 | 6.6 | 10.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Certara (CERT)
| -17.3 | -39.2 | 9.5 | -43.5 | -15.7 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Certara (CERT)
|
8.4 | 1,285.9 | 408.5 | -68.4 | 7.8 | -6.7 | -- | 1.4 |
| 232.1 | 7,947.6 | 1,040.9 | 157.5 | 17.9 | 29.5 | 49.8 | 14.7 | |
| 5.7 | 12,505.9 | 5.0 | -900.0 | -17,920.0 | -44 | -- | 6.3 | |
| 24.6 | 7,330.9 | 825.7 | -48.1 | -0.5 | -2.3 | -- | 3.6 | |
| 35.9 | 7,495.3 | 2,531.6 | 442.8 | 27.9 | -- | 19 | 29.8 | |
| 93.4 | 8,812.5 | 1,337.2 | 230.7 | 24.7 | 11 | 39 | 4.3 | |
| 20.6 | 10,498.6 | 1,121.1 | -157.4 | -17.8 | -2.3 | -- | 1.5 | |
| 22.8 | 7,178.3 | 1,048.9 | -318.7 | -27.7 | -21.3 | -- | 5.1 | |
| 18.3 | 8,248.5 | 1,672.3 | 327.4 | 8.3 | 17.1 | 26.5 | 4.3 | |
| 30.2 | 6,990.7 | 1,570.9 | -2.2 | -0.5 | -0.3 | -- | 7.8 |
Shareholding Pattern
View DetailsAbout Certara (CERT)
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the... Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania. Read more
-
CEO & Director
Dr. William F. Feehery Ph.D.
-
CEO & Director
Dr. William F. Feehery Ph.D.
-
Headquarters
Radnor, PA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Certara (CERT)
What is the current share price of Certara Inc (CERT) Today?
The share price of Certara Inc (CERT) is $8.41 (NASDAQ) as of 27-Aug-2026 16:18 EDT. Certara Inc (CERT) has given a return of -19.5% in the last 3 years.
What is the current PB & PE ratio of Certara Inc (CERT)?
Since, TTM earnings of Certara Inc (CERT) is negative, P/E ratio is not available.
The P/B ratio of Certara Inc (CERT) is 1.38 times as on 21-Aug-2026, a 82 discount to its peers’ median range of 7.80 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-885.94 |
1.33 |
2024 |
-142.52 |
1.62 |
2023 |
-50.66 |
2.68 |
2022 |
173.72 |
2.37 |
2021 |
-333.40 |
4.25 |
What is the 52 Week High and Low of Certara Inc (CERT)?
The 52-week high and low of Certara Inc (CERT) are Rs 13.88 and Rs 4.45 as of 28-Aug-2026.
What is the market cap of Certara Inc (CERT)?
Certara Inc (CERT) has a market capitalisation of $ 1,286 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Certara Inc (CERT)?
Before investing in Certara Inc (CERT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.